Humana Inc vs Micron Technology, Inc. — how do they compare? Humana Inc trades at $436.75 (market cap $46.49B), while Micron Technology, Inc. trades at $1,024.46 (market cap $1.17T). The key difference: Micron Technology, Inc. is far larger — about 25.2× Humana Inc's market cap, and Humana Inc pays the higher dividend (0.91%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Micron Technology, Inc. for 48 Days on average.
| HUM | MU | |
|---|---|---|
Market Cap | $46.49B | $1.17T |
Volume | 2,567,704 | 29,425,906 |
Sector | Health | Technology |
52-Week High | $409.85 | $1.21K |
52-Week Low | $163.67 | $181.60 |
Typical Hold Time | 53 Days | 48 Days |
Enterprise Value | $53.84B | $1.13T |
Dividend Yield | 0.91% | 0.06% |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $441.74, up 11.41% over 24 hours, reflecting strong momentum. The stock shows bullish technical signals with support at $391 and resistance at $406. Fundamentally, revenue grew to $129.66B in 2025, though net income margin compressed to 0.88%. Recent news highlights a Barclays upgrade to a $515 price target and upcoming Q3 earnings on November 6, 2026.
The outlook is cautiously optimistic with a consensus price target of $457.05 implying modest upside. Risks include margin pressure from Medicare Advantage plan changes and potential regulatory scrutiny. Institutional activity is mixed, with Bank of America adding a position while some funds reduced stakes.
Micron Technology (MU) trades at $1,088, up 4.06% with strong bullish momentum, supported by consecutive earnings beats and robust AI-driven memory demand. The stock shows impressive fundamentals with 63.8% net margins and 91.77% ROE, while technical indicators signal bullish moving averages. Recent strategic customer agreements covering 35% of revenue through 2030 provide visibility, though growth deceleration concerns linger.
Outlook remains positive with analyst consensus at $1,590 price target (82.85% buy ratings), but risks include cyclical memory pricing, competitive pressures, and potential AI demand normalization. The stock's valuation appears reasonable with P/E of 13.94, supporting continued upside if execution persists.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →